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Abstract
Aims To investigate the associations of the apolipoprotein E phenotype (apoE)
and disturbed glucose metabolism with cognitive function in a random
population sample.
Methods A cross-sectional study was conducted, in which 528 men aged 54 or
60 years were recruited randomly from a larger population-based sample of
1516 men. A subject was de®ned as having abnormal glucose tolerance (AGT),
if he had a clinical diagnosis of diabetes, with either dietary or oral
antidiabetic treatment or showed impaired glucose tolerance in an oral glucose
tolerance test. The subjects were divided into three groups according to
apolipoprotein E phenotypes: (a) E2/4, E3/4 or E4/4 (apoE E4); (b) E 3/3
(apoE E3); and (c) E2/2 or E2/3 (apoE E2). Memory function was examined
using a word-list learning with Buschke's selective reminding method and test.
Executive functions were assessed with the Trail Making Test A and B.
Results Those subjects with apoE E2 and abnormal glucose metabolism
demonstrated the worst cognitive executive control compared to other groups.
Simple cognitive speed did not differ between the groups.
Conclusions The exploratory analyses revealed that subjects with apoE E2
allele and AGT had worse glycaemic control and cognitive executive control
compared to other groups. Different apolipoprotein phenotypes together with
impaired glucose tolerance may have different cumulative adverse effects on
age-related cognitive performance. Some subgroups of subjects may be
especially vulnerable to cognitive impairment.
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Abbreviations AGT, abnormal glucose tolerance; NGT, normal glucose
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Introduction
The apolipoprotein E (apoE) E4 allele is an important risk
factor for Alzheimer's disease [1,2]. The apoE E4 allele has
Correspondence to: Eeva-Liisa Helkala, PhD., Department of Public Health
and General Practice, University of Kuopio, P.O.Box 1627, SF-70211 Kuopio,
Finland. E-mail: Eeva-Liisa.Helkala@uku.®
*Department of Public Health and General
Practice of University of Kuopio, Kuopio, Finland,
²Research Institute of Public Health, University of
Kuopio and ³Research Institute of Exercise
Medicine, Kuopio, § Department of Neurology,
University Hospital and University of Kuopio,
Kuopio, Finland, **National Public Health
Institute, Helsinki, Finland, ²²Department of
Epidemiology, University of Michigan, School of
Public Health, Ann Arbor, Michigan, USA
Accepted 10 May 2001
ã 2001 Diabetes UK. Diabetic Medicine, 18, 991±997 991
also been associated with decreased cognitive function in
discordant twin pairs [3]. In that study, the authors suggest
that E4 may represent a potential marker for accelerated
cognitive ageing. Episodic memory decline [4] or cognitive
decline [5] has been shown in older adults carrying the
apoE E4 allele. The apoE E2 allele may play a protective
role in normal ageing [6]. A cross-sectional study showed
that the E2 allele is associated with better learning ability in
nondemented elderly subjects [7]. A longitudinal popula-
tion-based study showed that subjects with the apoE
phenotypes E2/2 or 2/3 were able to maintain their verbal
learning performance, while the learning ability of subjects
with other apoE phenotypes deteriorated [8].
Patients with noninsulin-dependent diabetes mellitus
(NIDDM) often show mild cognitive impairment
[9,11,12]. It has been suggested that the presence of apoE
phenotypes containing the E4 allele and cerebrovascular
disease may have a synergistic effect on cognitive decline
[13,14]. We investigated whether different apoE pheno-
types and diabetes or impaired glucose tolerance had a
cumulative adverse effect on cognitive performance in a
population-based sample of middle-aged men in eastern
Finland. In addition, we assessed the role of possible
mediators of this relationship, such as control of glucose
and lipid metabolism and cardiovascular diseases.
Subjects and methods
Subjects
The subjects were participants in the Kuopio Ischemic Heart
Disease Risk Factor Study (KIHD). The recruitment of the
subjects has been explained in detail previously [15]. The KIHD
study was approved by the Research Ethics Committee of the
University of Kuopio, Kuopio, Finland and all subjects gave
written informed consent. The second cohort of the study
population of the KIHD consisted of 1516 men aged 42, 48, 54
and 60 years (82.6% of those eligible) at the time of examin-
ation. A total of 1229 men underwent ultrasound examination
of the right and left carotid arteries. The group was invited to
participate in a follow-up study four years later. Cognitive
examination was performed in the two oldest age groups of 555
men. Nine men did not participate in the cognitive examination.
Due to missing data on glucose metabolism, 528 men were
included in the ®nal analyses. Of these men, none were receiving
insulin treatment, 43 had NIDDM and 105 had IGT, according
to the WHO criteria [16].
Methods
Measurement of glucose tolerance
A 2 h oral glucose tolerance test (OGTT) was performed with a
75 g glucose load after at least 12 h of overnight fasting. Blood
glucose was measured from fresh whole blood prior to, and two
hours after, the glucose load using the glucose dehyrogenase
method, after precipitation of proteins with tricloracetic acid.
De®nition of NIDDM and IGT
A subject was considered to have noninsulin-diabetes (NIDDM)
if he had a clinical diagnosis of diabetes and was undergoing
either dietary or oral antidiabetic treatment or had a fasting
venous blood glucose > 6.7 mmol/L or 2 h venous blood
glucose > 10.0 mmol/L. IGT was de®ned as a fasting venous
blood glucose < 6.7 mmol/L and 2 h venous blood glucose 6.7±
10.0 mmol/L. A subject was de®ned as having an abnormal
glucose tolerance (AGT) if he had either NIDDM or IGT.
Measurement of serum insulin
Fasting and 2 h serum insulin in OGTT was determined from
frozen serum samples with radioimmunological methods
(Pharmacia, Uppsala, Sweden). Serum glycated proteins were
measured with an autoanalyser (Kone Speci®c, Espoo, Finland).
Resting blood pressure
This was measured between 8:00 and 9:00 a.m. using a random-
zero mercury sphygmomanometer (Hawsley, United Kindom).
After a supine rest of ®ve minutes, three measurements were
taken in the supine, one in the standing and two in the sitting
position at ®ve minutes intervals. The mean of these six
measurements was used.
Waist-to-hip ratio
The waist-to-hip ratio was computed as the ratio of the
circumference of the waist to the circumference of the hip.
Body mass index
This was calculated as weight divided by height squared (kg/m2).
Medical history
This was recorded with a self-administered questionnaire,
checked by a physician.
The apolipoprotein E phenotype
This was determined from plasma with isoelectric focusing and
immunoblotting techniques [17]. The subjects were divided into
three groups according to apolipoprotein E phenotypes.
Subjects having one or two apolipoprotein e4 alleles were
included in the apoE E4 group. Subjects with the most common
apolipoprotein E phenotype, E3/3, formed the apoE E3 group
and subjects with apolipoprotein E2/2 or E2/3 made up the apoE
E2 group.
Cognitive measurements
Memory function was examined using a word-list learning test
using Buschke's selective reminding method (BSRT) [18]. The
subjects were read 10 unrelated words and were asked for
immediate recall of the entire list. On the second trial, the
subjects were read only those words that they failed to recall on
the ®rst trial and were again asked to recall the entire list. The
score was the sum of words recalled on six trials. Executive
functions were examined by the Trail Making Test A (TMTA)
and B (TMTB) [19]. In Trail Making Test B, the letters were
replaced with the names of the months using the ®rst three letters
of each month. The time in seconds to complete each trial was
recorded. A maximum time of 150 s for Trail Making Test A,
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and 300 s for Trail Making Test B were allowed. If the test was
not completed in the time allowed, the missing letters or
numbers were scored as errors. The difference between times to
complete the A and B parts was used as an indication of cognitive
dif®culty in changing between targets.
Statistical analysis
Statistical analyses were conducted with the SPSS for Windows
Release 9.0. The differences between the groups were assessed
uisng analysis of variance. The c2±test was used for dichot-
omous variables.
The association of apoE phenotype and AGT on cognitive
impairment was analysed with analysis of variance adjusted for
age group and education. We also adjusted the results for
possible confounders: serum HDL cholesterol, BMI, cardiovas-
cular diseases and medication. We furthermore adjusted the
results for serum glycated proteins, fasting serum blood glucose,
2 h blood glucose, fasting serum insulin, or 2 h serum insulin.
Results
Characteristics of ApoE and AGT groups
Percentages of subjects in the two age groups were similar
in the different apoE groups. Education did not differ
between the different apoE groups. The subjects with apoE
E2 had higher fasting blood glucose, 2 h glucose, fasting
insulin, and serum triglycerides than subjects with other
phenotypes (Table 1). Education or age group distribution
did not differ between the NGT and AGT groups (data not
shown). AGT was related to higher BMI, waist-to-hip
ratio, serum glycated proteins, fasting and 2 h blood
glucose, fasting and 2 h serum insulin, diastolic blood
pressure, and lower serum HDL cholesterol (data not
shown).
Association between apoE phenotype and glycaemic
control
Serum glycated proteins, fasting blood glucose, and 2 h
blood glucose were higher in the apoE E2 group than in
other groups (Table 1). The AGT subjects with an apoE E2
allele had highest levels of serum glycated proteins
[F2,527 = 7.19, P < 0.001 for the interaction] (Fig. 1),
fasting blood glucose [F2,527 = 99.7, P < 0.003 for the
interaction] (data not shown) and 2 h blood glucose
[F2,527 = 6.45, P < 0.002 for the interaction] (Fig. 2).
Association between apoE phenotype, AGT and
cognitive function
Executive or memory functions did not differ in the
different apoE groups or between the AGT and NGT
groups (data not shown). However, the subjects with AGT
and the apoE E2 allele performed worst on Trail Making
Test B after adjustment for education and age group
(Table 2). The performance was, nevertheless, within
normal range. Although the variance in Trail Making
Test was greatest in subjects with the apoE E2 allele with
AGT, the median of Trail Making Test was also lower in
this group than in the other groups. Furthermore, the
median was close to the mean in the apoE E2 group. Men
with the apoE E2 allele and AGT also performed worst in
Trail Making Test B±A (Table 2). The results of Trail
Making Test A and word list learning did not differ
between the groups. The analyses were also performed in
the IGT, NIDDM, and NGT groups, but the results were
essentially the same.
Analyses of possible confounding factors
When serum glycated proteins, fasting blood glucose,
blood 2 h glucose, fasting insulin, 2 h insulin, serum HDL
cholesterol, or BMI was used alone as a covariate, the
results did not change (data not shown). When education
and age group were added into model as covariates,
together with serum glycated proteins, fasting blood
glucose, 2 h blood glucose, or fasting insulin, the results
did not change (Table 3). The regression coef®cients and
95% con®dence intervals of the relationship of abnormal
glucose tolerance and apoE E2 phenotype compared to
other apoE phenotypes and glucose tolerance groups to
Trail Making Test B and Trail Making Test B-A are
presented in Table 3. When age group without education
was in the model with serum glycated proteins, fasting
blood glucose, 2 h blood glucose, or fasting insulin, the
signi®cance disappeared. Potentially mediating factors
such as cardiovascular diseases, i.e. cardiomyopathia,
cardiac insuf®ciency, angina pectoris, claudication or
hypertension, and medications, i.e. any drug for hyperten-
sion, diuretics, or any b-blocker, did not explain the results.
The exclusion of stroke patients from the analyses did not
change the results.
Discussion
In the present study, subjects with the apoE E2 allele had
poorer glycaemic control than subjects with other apoE
phenotypes. Subjects with AGT and apoE E2 allele also
performed less well in their cognitive executive control
compared to those with other apoE phenotypes or NGT.
We did not ®nd any independent association between
cognitive function and AGT or between cognitive function
and apoE phenotype.
The association of apoE phenotype and abnormalities of
glucose regulation has been previously studied in patients
with dementia. Hyperinsulinaemia was associated with an
increased risk for Alzheimer's disease in nondiabetic
subjects without the ApoE E4 allele [20]. Higher fasting
plasma insulin levels and reduced cerebrospinal ¯uid-to-
plasma insulin ratios, indication of insulin resistance, have
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been observed in patients with Alzheimer's disease who do
not possess an apolipoprotein E e4 allele [21]. This ®nding
suggests that there is a difference in insulin metabolism in
E4 homozygotes compared with the non-E4 homozygotes
with respect to Alzheimer's disease. In the present study,
the highest fasting and 2 h blood glucose, and fasting
serum insulin values were associated with apoE E2 allele in
a normal population.
The mechanisms of cognitive impairment related to
NIDDM are not fully understood. The chronic hypergly-
caemia, typical of NIDDM, may link diabetes and cogni-
tive function. Epidemiological studies have found poorer
cognitive performance to be associated with NIDDM
[22,23] and with impaired glucose tolerance [24,25].
Longitudinal studies have also shown an association
between diabetes mellitus and Alzheimer's disease
[26,27]. Some have demonstrated that poor glycaemic
control as assessed by HbA1c correlates with cognitive
decrement [9,28,29] but others have not [30,31]. No
correlation has been found between cognitive performance
and fasting blood glucose [28,32]. In a small clinical
sample, improved glycaemic control in the elderly patients
with NIDDM led to better cognitive performance [33].
Impaired verbal memory has been most frequently found
[28±30,34] but associations with impaired attention or
concentration [29,35,36] have also been reported. The
formation of advanced glycation end products contribute
to the pathogenesis of diabetic complications, but could
contribute to the characteristic protein deposits in
Alzheimer's disease, including neuro®brillary tangles
and beta-amyloid plaques [37,38]. However, the serum













54 year-old age group 5.1 30.6 16.1 Ns
60 year-old age group 3.0 29.7 15.3 Ns
Education, years 8.8 (3.0) 8.2 (3.0) 7.6 (2.9) Ns
Body mass index (kg/m2) 28.4 (4.6) 27.4 (3.4) 27.8 (3.9) Ns
Waist-to-hip ratio 1.02 (0.04) 1.00 (0.05) 1.01 (0.04) Ns
Serum glycated proteins (Umol/L) 246.0 (41.1) 237.7 (26.7) 239.90 (34.7) Ns
Fasting blood glucose (mmol/L) 5.6 (1.7) 5.0 (0.9) 5.2 (1.5) 0.007
2 h blood glucose (mmol/L) 6.8 (4.3) 5.8 (2.3) 6.5 (3.2) 0.016
Fasting serum insulin (mUL/L) 10.4 (8.0) 7.7 (4.5) 9.3 (7.4) 0.001
2 h serum insulin (mUL/L) 55.1 (47.9) 52.9 (41.7) 63.9 (67.2) 0.079
Serum triglycerides (mmol/L) 2.0 (1.1) 1.5 (0.7) 1.7 (1.0) 0.000
Serum HDL cholesterol (mmol/L) 1.1 (0.3) 1.1 (0.3) 1.0 (0.3) 0.083
Systolic blood pressure (mmHg) 144.0 (19.5) 138.8 (16.8) 138.6 (15.4) Ns
Diastolic blood pressure (mmHg) 93.0 (9.6) 88.4 (10.3) 88.9 (9.5) 0.018
Stroke % 2.3 3.4 4.8 Ns
Cardiomyopathia % 0 0.9 1.2 Ns
Cardiac insuf®ciency % 11.6 9.7 11.4 Ns
Angina pectoris % 20.9 19.5 24.1 Ns
Claudication % 9.3 8.2 5.5 Ns
Hypertension % 48.8 33.0 42.2 Ns
Drug for hypertension % 46.5 32.3 44.0 Ns
Diuretics % 4.7 2.2 4.2 Ns
Any b-blocker % 11.6 14.1 19.3 Ns
Diabetes/IGT % 11.6/23.3 6.3/19.7 10.8/19.3 Ns
Diabetes four years earlier % 9.3 2.5 4.8 0.064
P1 = Analysis of variance, main effect of apoE group.
Figure 1 Serum glycated proteins (umol/L) in different apoE groups
with normal (NGT) and abnormal (AGT) glucose tolerance.
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glycated proteins did not differ between apoE groups in the
present study.
Duration of diabetes has been related to cognitive
decline [22,40]. Croxson et al. [41] reported that those
with known diabetes were more likely than normal
subjects to have a low Mini Mental Status Examination
score, while newly diagnosed diabetic subjects did not.
However, we do not know how long the glycaemic control
has been poor in our subjects.
Insulin might also affect neuronal activity and cognition.
An association between high postload insulin and glucose
levels, and poor cognitive function has been reported [23].
Moreover, Craft et al. [42] recently showed that insulin
administration improved memory performance in
Alzheimer's disease subjects without an e4 allele, whereas
the memory performance of the Alzheimer's disease e4
patients did not improve. This suggests that glycaemic
control may be related to cognitive impairment in a
subgroup of Alzheimer's disease patients only. This is
partly supported by our observation that only subjects with
an apoE E2 allele and AGT performed more poorly than
those with AGT and other alleles.
Table 2 Executive and memory function in men with abnormal glucose tolerance (AGT) and normal glucose tolerance (NGT) with different
apolipoprotein E phenotypes (apoE)


















Mean (SD) P1 P2 P3
Trail Making A 51.7(15.0) 53.9(17.2) 48.7(15.5) 52.3(16.9) 52.3(20.0) 55.3(20.7) Ns 0.000 0.061
Trail Making B 145.1(89.5) 131.0(64.5) 123.7(70.3) 102.0(48.0) 121.5(63.2) 139.3(68.1) 0.027 0.001 0.001
Trail Making B-A 93.2(81.2) 77.5(56.4) 75.0(59.6) 49.6(44.0) 69.2(50.0) 84.1(58.9) 0.029 0.001 0.001
List learning 34.1(7.9) 33.1(8.1) 34.6(7.9) 34.7(8.1) 34.7(8.7) 33.7(8.9) Ns 0.001 0.015
Analysis of variance, adjusted for agegroup and education, P1 Interaction between AGT and ApoE groups, P2 Effect of education, P3 Effect of
age group. The values of cognitive tests are within normal range.
Figure 2 2 h blood glucose (mmol/L) in glucose tolerance test in
different apoE groups with normal (NGT) and abnormal (AGT)
glucose tolerance.
Table 3 Regression coef®cients (95% Con®dence interval) of
abnormal glucose tolerance and apoE E2 phenotype to Trail Making
Test B and Trail Making Test B-A
Trail Making Test B
b-coef®cient (95% CI)
Trail Making Test B-A
b-coef®cient (95% CI)
Model 1: 58.61 (11.85±105.37) 52.68 (13.47±91.88)
Model 2: 65.07 (21.52±108.62 57.36 (20.14±94.59)
Model 3: 56.21 (12.84±99.57) 50.01 (12.92±87.10)
Model 4. 55.16 (11.75±98.56) 48.89 (11.78±85.99)
Model 5: 55.13 (11.68±98.58) 48.72 (11.58±85.85)
Model 6: 56.39 (12.86±99.92) 49.44 (12.22±86.65)
Model 7: 56.47 (13.12±99.94) 50.32 (13.14±87.49)
Model 8: 56.15 (12.75±99.55) 49.98 (12.86±87.11)
Model 9: 57.25 (14.17±100.87) 50.99 (13.89±88.09)
Model 10: 56.19 (12.75±99.63) 49.90 (12.74±87.05)
Model 11: 58.75 (15.05±102.46) 51.44 (14.04±88.84)
Model 1: Unadjusted association of AGT 3 apoE E2
Model 2: Controlling for education
Model 3: Controlling for education and age group
Model 4: Controlling for education, age group, and serum glycated
proteins
Model 5: Controlling for education, age group, and fasting blood
glucose
Model 6: Controlling for education, age group, and 2 h blood
glucose(mmol/L)
Model 7: Controlling for education, age group, and fasting serum
insulin (mUL/L)
Model 8: Controlling for education, age group, and serum
triglycerides (mmol/L)
Model 9: Controlling for education, age group, and diastolic blood
pressure (mmHg)
Model 10: Controlling for education, age group, and body mass
index (kg/m2)
Model 11: Controlling for education, age group, serum glycated
proteins, fasting blood glucose, 2 h blood glucose (mmol/L), fasting
serum insulin (mUL/L), triglycerides (mmol/L), diastolic blood
pressure (mmHg), and body mass index (kg/m2).
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It is possible that other aspects related to the insulin
resistance syndrome, such as accelerated atherosclerosis
[14], could explain the association between the insulin
resistance syndrome and cognitive impairment in elderly. It
has been suggested that the presence of apolipoprotein E
phenotypes containing the e4 allele, cerebrovascular
disease [14] and cardiovascular risk factors or subclinical
cardiovascular disease [43] may act synergistically on
cognitive decline.
The absolute postprandial triglyceridaemia was highest
in subjects with apolipoprotein E2 allele [44]. They also
had increased factor (VIIa) activity during postprandial
triglyceridaemia. In the present study, the apoE E2 allele
group had higher serum triglycerides and diastolic blood
pressure. However, there was no difference in the preva-
lence of cardiovascular diseases between the groups.
These exploratory analyses revealed that subjects with
an apoE E2 allele and AGT exhibited worse cognitive
executive control than other subjects. They also had worse
glycaemic control. Different apolipoprotein phenotypes,
together with impaired glucose tolerance, may have
different cumulative adverse effects on age-related cogni-
tive performance. Some subgroups of subjects may be
especially vulnerable to cognitive impairment. These
®ndings require further study.
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